GWS
AST

Glassman Wealth Services’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

Glassman Wealth Services’s Portfolio AST Stock Details AST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-4
Closed – – 723
2017
Q1 		$0 Hold
4
– – ﹤0.01% 765
2016
Q4 		$0 Hold
4
– – ﹤0.01% 759
2016
Q3 		$0 Hold
4
– – ﹤0.01% 641
2016
Q2 		$0 Buy
+4
New +$14 ﹤0.01% 483

Other funds holding AST

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NFC
Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Glassman Wealth Services's AST Position: Q2 2017 in Review

Glassman Wealth Services sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q2 2017, closing a stake of 4 shares.

Glassman Wealth Services first reported a position in AST in Q2 2016 and held it in 4 quarters. The position peaked at $0 in Q1 2017. 64 funds tracked by Wall St. Rank hold AST as of Q2 2017.

  • Glassman Wealth Services reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q2 2017 after selling out during the quarter.
  • Glassman Wealth Services sold 4 Asterias Biotherapeutics Inc. Series A shares in Q2 2017.
  • Glassman Wealth Services first reported a position in Asterias Biotherapeutics Inc. Series A in Q2 2016 and held it in 4 quarters.
  • Glassman Wealth Services's Asterias Biotherapeutics Inc. Series A position peaked at $0 in Q1 2017.
  • 64 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q2 2017.

Based on Glassman Wealth Services's 13F filing for Q2 2017, filed 9 Aug 2017.